Key Quantitative Figures

  • Solar Capacity: 15.8 MW (increased from 10.8 MW in FY24-25)
  • Solar Generation: 1,70,18,414 kWh of clean electricity
  • Renewable Energy Share: 11.5% of total energy (up from 0.2%)
  • Energy Consumption: 5,31,497 GJ (increased 23% from 4,33,048 GJ)
  • GHG Emissions:
  • Scope 1: 23,730 tCO₂e (decreased 12% from 26,874 tCO₂e)
  • Scope 2: 27,675 tCO₂e (increased 67% from 16,552 tCO₂e)
  • Scope 3: 19,260 tCO₂e (increased 24% from 15,564 tCO₂e)
  • Water Withdrawal: 1,39,547 KL (increased 8% from 1,28,710 KL)
  • Water Consumption: 80,616 KL (increased 15% from 70,085 KL)
  • Waste Generated: 17,024 MT (increased 112% from 8,020 MT)
  • Waste Recycled: 85% (increased from 62%)
  • Workforce: 1,713 total (employees, workers and contract workers)
  • Safety Performance: Zero fatalities, zero lost-time injuries
  • CSR Spend: ₹28.81 million (increased from ₹19.77 million)
  • CSR Beneficiaries: ~8,000 people
  • MSME Procurement: 40% of total purchases (increased from 34%)

Dates of Action

  • Report Submission Date: November 07, 2026
  • Reporting Period: April 2025 to March 2026
  • Name Change Effective: May 15, 2025 (from Ami Organics Limited to Acutaas Chemicals Limited)
  • Battery Plant Inauguration: January 19, 2026
  • ESG Committee Meetings: Three meetings (April 23, 2025; August 19, 2025; January 23, 2026)

Parties Involved

  • Stock Exchanges: BSE Limited, National Stock Exchange of India Limited
  • Assurance Providers: TÜV SÜD South Asia Pvt. Ltd. (BRSR Core reasonable assurance), Anares Analytics LLP
  • Subsidiaries/JVs: Baba Fine Chemicals (55%), Indichem Inc. (75% via Acutaas Advance Material), Acutaas Chemicals Electrolytes Private Limited (90%)

Business Operations Impact

  • Production Change: Shift toward lower-volume, higher-value molecules requiring more processing per tonne
  • New Capacity: Phase I of battery chemicals plant at Jhagadia commissioned with 2,000 MTPA capacity each for VC and FEC
  • Geographic Expansion: Indichem Inc. R&D center operational in South Korea; plant inaugurated August 2026 (post year-end)
  • Product Mix: ~95% of pharmaceutical intermediates portfolio serves chronic therapies

Financial Impact

Not quantified in the disclosure beyond CSR spending and well-being expenditure of ₹65.96 million on employees and workers.

Capital Structure Impact

No direct impact on capital structure disclosed in this sustainability report.

Forward-Looking Statements

The report contains forward-looking statements about plans, targets and expectations subject to risks and uncertainties. The company is working towards science-based emission reduction targets for submission within 12-18 months and plans to participate in a global climate disclosure platform from FY 2026-27.

Assurance and Compliance

  • BRSR Core indicators received reasonable assurance from TÜV SÜD South Asia
  • Zero regulatory incidents, zero conflict-of-interest cases, zero confirmed data breaches
  • Responsible Care certification from Indian Chemical Council obtained in March 2026
  • EcoVadis rating upgraded from Gold to Platinum (top 1% globally) in August 2025
  • Great Place To Work® certification in May 2026